http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 16:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+01++Filed+by%3A+Yi+Qingqing/26598903.html si-local-file:///var/storage/secattach/20260603/26598903.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+01++Filed+by%3A+Yi+Qingqing/26598903.html Wed, 03 Jun 2026 16:10:00 -0400 688235 O.76306903 ONC http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+01++Filed+by%3A+Yi+Qingqing/26598903.html si-local-file:///var/storage/secattach/20260603/26598903.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+01++Filed+by%3A+Yi+Qingqing/26598903.html Wed, 03 Jun 2026 16:10:00 -0400 688235 O.76306903 ONC http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+01++Filed+by%3A+Yi+Qingqing/26598903.html si-local-file:///var/storage/secattach/20260603/26598903.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BeOne+Medicines+Ltd.++++++For%3A+Jun+01++Filed+by%3A+Yi+Qingqing/26598903.html Wed, 03 Jun 2026 16:10:00 -0400 688235 O.76306903 ONC http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Yi+Qingqing/26584139.html si-local-file:///var/storage/secattach/20260601/26584139.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Yi+Qingqing/26584139.html Mon, 01 Jun 2026 16:28:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Yi+Qingqing/26584139.html si-local-file:///var/storage/secattach/20260601/26584139.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Yi+Qingqing/26584139.html Mon, 01 Jun 2026 16:28:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Yi+Qingqing/26584139.html si-local-file:///var/storage/secattach/20260601/26584139.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BeOne+Medicines+Ltd.+++++++++++++++++++Filed+by%3A+Yi+Qingqing/26584139.html Mon, 01 Jun 2026 16:28:00 -0400 688235 BEIGF O.76306903 http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html <p class="bwalignc"> <i>Oral and poster presentations span three priority programs in breast, gynecologic, and gastrointestinal cancers, advancing rapidly toward pivotal development</i> </p><p class="bwalignc"> <i>Company to host investor webcast showcasing momentum across solid tumor pipeline</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54545081&amp;newsitemid=20260601948824&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=4ae4b7c009240667889b354b22736777" shape="rect">BeOne Medicines Ltd.</a> (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its solid tumor pipeline being presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago). These data underscore the significant acceleration across the Company’s high-priority breast, gynecologic and gastrointestinal (GI) cancer development programs. </p><p> Data from http://www.streetinsider.com/Business+Wire/BeOne+Medicines+Highlights+Accelerating+Solid+Tumor+Pipeline+with+New+Data+at+ASCO+2026/26578153.html Mon, 01 Jun 2026 06:00:00 -0400 06160 688235 A.50216726 A.60001765 O.20738543 O.21612337 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html <p class="bwalignc"> <i>Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy</i> </p><p class="bwalignc"> <i>BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL</i> </p><p class="bwalignc"> <i>Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54543794&amp;newsitemid=20260529392296&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=e0d28ffb8b98b505a00b52194f114df9" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html Fri, 29 May 2026 06:00:00 -0400 06160 688235 A.06822034 A.30678504 A.31034861 A.31066700 A.50216726 O.07123365 O.16683936 O.20026344 O.21612337 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html <p class="bwalignc"> <i>Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy</i> </p><p class="bwalignc"> <i>BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL</i> </p><p class="bwalignc"> <i>Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54543794&amp;newsitemid=20260529392296&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=e0d28ffb8b98b505a00b52194f114df9" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html Fri, 29 May 2026 06:00:00 -0400 06160 688235 A.06822034 A.30678504 A.31034861 A.31066700 A.50216726 O.07123365 O.16683936 O.20026344 O.21612337 O.22422661 O.76306903 ONC http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html <p class="bwalignc"> <i>Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapy</i> </p><p class="bwalignc"> <i>BRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLL</i> </p><p class="bwalignc"> <i>Data reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise</i> </p> <p> SAN CARLOS, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54543794&amp;newsitemid=20260529392296&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=e0d28ffb8b98b505a00b52194f114df9" shape="rect">BeOne Medicines Ltd.</a> (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society http://www.streetinsider.com/Press+Releases/BeOne+Medicines+Establishes+Standard+for+Long-Term+Disease+Control+in+CLL+with+BRUKINSA+78-Month+Data+at+ASCO+2026/26570024.html Fri, 29 May 2026 06:00:00 -0400 06160 688235 A.06822034 A.30678504 A.31034861 A.31066700 A.50216726 O.07123365 O.16683936 O.20026344 O.21612337 O.22422661 O.76306903 ONC